{
    "clinical_study": {
        "@rank": "163246", 
        "acronym": "ARISTOCRAT", 
        "arm_group": [
            {
                "arm_group_label": "Standard Manual Compression", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard manual compression at the access site applied as per standard of care protocol for sheath removal."
            }, 
            {
                "arm_group_label": "AXERA 2 Access System", 
                "arm_group_type": "Active Comparator", 
                "description": "The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of the research study is to observe the clinical safety, effectiveness and patient\n      satisfaction of the AXERA 2 Access System in subjects undergoing coronary angiographic and\n      possible Percutaneous Coronary Intervention (PCI) through the femoral artery when compared\n      to standard manual compression."
        }, 
        "brief_title": "ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access System", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a single center  1:1 randomized controlled trial in subjects undergoing\n      coronary angiography and PCI.\n\n      It is anticipated that the enrollment period for this study will be one year.\n\n      The post procedure follow up period is up to 37 days following the procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is between 18 and 85 years of age.\n\n          -  Cardiac catheterization procedure is indicated with involving access through a 5\n             French (F) or 6 French (F) introducer in the femoral artery.\n\n          -  Subject is able to ambulate without assistance prior to the procedure and can be\n             expected to ambulate (20 feet) post-procedure.\n\n          -  Subject or legally authorized representative has signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Subject is unable to routinely 20 feet without assistance (e.g. requires a walker or\n             wheelchair to mobilize or has paralysis)\n\n          -  Subject has an active systemic or cutaneous infection or inflammation (e.g.\n             (septicemia at the time of the procedure).\n\n          -  Subject undergoing emergent or urgent cardiac catheterization for acute myocardial\n             infarction.\n\n          -  Extensive calcification of the femoral artery as see on fluoroscopy.\n\n          -  Subject has systemic hypertension unresponsive to treatment (>180mm Hg systolic and\n             >110mm Hg diastolic).\n\n          -  Subject has received thrombolytic therapy within the 72 hours prior to\n             catheterization.\n\n          -  Subject has known bleeding disorder,such as Factor 5  deficiency, Idiopathic\n             thrombocytopenic purpura (ITP), thrombasthenia, Von Willebrand's disease.\n\n          -  Is on warfarin with an International Ratio (INR)1.5.\n\n          -  Platelet count is < 100,000.\n\n          -  Anemia (Hemoglobin <10 g/dl or Hematocrit<30%).\n\n          -  Subject has compromised femoral artery access site.\n\n          -  Subject procedure requires an introducer sheath size of > 6 French (F).\n\n          -  Subject has had prior vascular surgery or vascular grafts at the femoral artery\n             access site.\n\n          -  Subject presents with hemodynamic instability or is in need of emergent surgery.\n\n          -  Subject has received femoral artery closure on the target access vessel with a\n             collagen/PEG closure device within 90 days.\n\n          -  Subject has a pre-existing severe non-cardiac systemic disease or illness that\n             results in an expected life expectancy of < 1 year.\n\n          -  Subject is participating in an investigational drug or another device research study\n             that interferes with the current research study endpoints.\n\n          -  Pregnant or lactating subjects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061696", 
            "org_study_id": "BRI-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AXERA 2 Access System", 
                "description": "AXERA 2 Access System with Reduced Manual Compression", 
                "intervention_name": "Vascular Access Device", 
                "intervention_type": "Device", 
                "other_name": "AXERA 2 Access System"
            }, 
            {
                "arm_group_label": "Standard Manual Compression", 
                "description": "Closure procedure by Manual Compression", 
                "intervention_name": "Standard Manual Compression", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Coronary Artery Disease", 
            "Coronary Disease", 
            "Heart disease", 
            "Cardiovascular Diseases", 
            "Arteriosclerosis", 
            "Atherosclerosis", 
            "Manual Compression"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "frank.saltiel@borgess.com", 
                "last_name": "Frank Saltiel, MD", 
                "phone": "269-381-3963"
            }, 
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "49048"
                }, 
                "name": "Borgess Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Frank Saltiel, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Vishal Gupta, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tim Fischell, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Poorna Karuparthi, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nitin Mahajan, M.D., MPH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Babatunde Komolafe, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial to Assess Safety and Efficacy of AXERA (Device Name) 2 Access System Compared to Manual Compression", 
        "other_outcome": [
            {
                "description": "Assessed by a patient satisfaction questionnaire.", 
                "measure": "Patient Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "Upt to 37 days post procedure"
            }, 
            {
                "measure": "Pain Score", 
                "safety_issue": "No", 
                "time_frame": "Up to 37 days post procedure"
            }
        ], 
        "overall_contact": {
            "email": "frank.saltiel@borgess.com", 
            "last_name": "Frank Saltiel, MD", 
            "phone": "269-381-3963"
        }, 
        "overall_contact_backup": {
            "email": "vishal.gupta@borgess.com", 
            "last_name": "Vishal Gupta, MD", 
            "phone": "269-226-5059"
        }, 
        "overall_official": {
            "affiliation": "Chairman, Borgess Heart Institute", 
            "last_name": "Frank Saltiel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Observation of any major access site related related complications (percentage of participants).", 
            "measure": "Observation of Any Site Related Major Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 37 days post procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061696"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Borgess Research Institute", 
            "investigator_full_name": "Frank Saltiel, MD", 
            "investigator_title": "Borgess Heart Institute, Chairman", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Achievement of femoral artery access with AXERA and placement of procedural sheath.", 
                "measure": "AXERA 2 Access System Success", 
                "safety_issue": "Yes", 
                "time_frame": "At the time of the femoral artery access procedure up to 1 hour post procedure"
            }, 
            {
                "description": "Difference between the time the procedural sheath is removed and hemostasis is observed.", 
                "measure": "Time to Hemostasis", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed from procedureal sheath removal until hemostasis is achieved, an average of 15 minutes"
            }, 
            {
                "description": "The time from sheath removal and ambulation to when subject can be discharged after examination of access site.", 
                "measure": "Time to Discharge Eligibility", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 day post procedure"
            }, 
            {
                "description": "Discharge following procedural sheath removal until actual discharge.", 
                "measure": "Time to Actual Discharge", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 day post procedure"
            }, 
            {
                "description": "The time the procedural sheath is removed and the subject can stand or walk 20 ft without rebleeding. Ambulation to be evaluated at 1, 2, and 4 hours post sheath removal until the subject can ambulate.", 
                "measure": "Time to Ambulation", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 day post procedure"
            }, 
            {
                "description": "Defined as the ability to sit up at 45 degree angle within 15 minutes of successful hemostasis without re-bleed", 
                "measure": "Ability to sit up at a 45 degree angle", 
                "safety_issue": "No", 
                "time_frame": "within 15 minutes of successful hemostasis"
            }, 
            {
                "description": "Observation of any minor access site related complications.", 
                "measure": "Minor Access Site Related Complications", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 37 days post procedure"
            }
        ], 
        "source": "Borgess Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Borgess Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Borgess Cardiology Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Borgess Heart Center for Excellence", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Frank Saltiel, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}